Effect of peritoneal dialysis in end-stage renal disease on apixaban pharmacokinetics.

Limited pharmacokinetics data are guiding the use of apixaban in end-stage renal disease (ESRD) patients on hemodialysis but none on peritoneal dialysis. Our study supports the cautious reduction of apixaban dose from 5 to 2.5 mg twice daily for ESRD patients on peritoneal dialysis, subject to further pharmacokinetics/pharmacodynamics studies and clinical trials. In this first pharmacokinetics study of apixaban in patients with ESRD on peritoneal dialysis, we demonstrated differences in pharmacokinetic parameters in comparison with a normal renal function population. [Extracted from the article]